Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-102 in Acute Schizophrenia
NCT07363577Phase 3Recruiting
- Sponsor
- LB Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LP-102 in schizophrenia (3 arms), sponsored by LB Pharmaceuticals. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Mar 2026; status: recruiting.
02
Drugs
LP-102
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07363577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363577.